K-BASKET, TAS-117, PI3K/AKT Gene Aberration

A Phase II Study of TAS-117 in Advanced Solid Tumors With PI3K/AKT Gene Aberration (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)

The phosphatidylinositol 3-kinase (PI3K)-v-akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) signaling pathway is one of the most frequently aberrantly regulated pathways in human tumors. TAS-117 is a highly potent and selective oral allosteric AKT inhibitor. It has high affinity for AKT1, 2, and 3 and shows potent anti-proliferative activity against multiple tumor cell lines in vivo. Therefore, we propose to conduct a phase II trial of TAS-117, potent and selective AKT inhibitor, in patients with advanced solid tumor with PI3K/AKT genetic aberrancy by NGS focusing panel in part of K-BASKET trial.

Study Overview

• Status: Completed
• Conditions: Solid Tumor, Adult
• Intervention / Treatment: Drug: TAS-117

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 2

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 03722
    • Severance Hospital, Yonsei University Health System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 17 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Histologically or cytologically confirmed recurrent or advanced solid cancers with PI3K/ATK aberration
2. Progressive disease who failed to previous standard treatment.
3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria
4. Eastern Cooperative Oncology Group performance status 0 or 1
5. Able to take medications orally
6. Adequate organ function
7. A life expectancy of at least 60 days

Exclusion Criteria:

1. Previous treatment with anti-PI3K or AKT directed therapies
2. Known hypersensitivity to any drugs similar to TAS-117 in structure or class.
3. History or current evidence of type 1 or type 2 diabetes mellitus that requires insulin and/or oral antidiabetic therapy.
4. Current evidence of retinopathy that requires ophthalmological therapy.
5. History or current evidence of cardiac arrhythmia and/or conduction abnormality.

6. Treatment with any of the following within the specified time frame prior to study drug administration:

   • Major surgery within prior 4 weeks
   • Radiation therapy for extended field within 4 weeks prior to study drug administration or limited field radiation therapy within 2 weeks prior to study drug administration.
   • Any anticancer treatment within 3 weeks prior to study drug administration (mitomycin within prior 5 weeks).
7. A serious illness or medical condition(s)
8. Unresolved toxicity of Grade >1 attributed to any prior therapies (excluding alopecia, skin pigmentation and anemia).
9. Patients with the risk of hypokalemia
10. Receiving oral steroid medication.
11. Pregnant or lactating female

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TAS-117; TAS-117, 16mg, orally, daily	Drug: TAS-117; TAS-117 16mg, daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
overall response rate	2 months

Collaborators and Investigators

• Sponsor: Yonsei University

Publications and helpful links

General Publications

• Lee JB, Jung M, Beom SH, Kim GM, Kim HR, Choi HJ, Sohn JH, Ahn JB, Rha SY, Chung HC. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Invest New Drugs. 2021 Oct;39(5):1366-1374. doi: 10.1007/s10637-021-01085-7. Epub 2021 Mar 15.

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2017
• Primary Completion (Actual): December 31, 2019
• Study Completion (Actual): December 31, 2019

Study Registration Dates

• First Submitted: January 9, 2017
• First Submitted That Met QC Criteria: January 10, 2017
• First Posted (Estimate): January 11, 2017

Study Record Updates

• Last Update Posted (Actual): April 22, 2021
• Last Update Submitted That Met QC Criteria: April 21, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: AKT inhibitor; Refractory solid tumors
• Other Study ID Numbers: 4-2016-0743

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No